Oops, that page doesn't exist!
Looks like you've found a page that doesn't exist. Please use the buttons to get back into the section of the site you were previously in.
Adverse events should be reported. In the United Kingdom, reporting forms and information can be found at https://yellowcard.mhra.gov.uk.
Adverse events should also be reported to Takeda on 01628 537900 or e-mail DSO-UK@takeda.com.
Reporting adverse events (UK Healthcare Professionals)
Adverse events should be reported. In the United Kingdom, reporting forms and information can be found at https://yellowcard.mhra.gov.uk. Adverse events should also be reported to Takeda on 01628 537900 or e-mail DSO-UK@takeda.com.
Reporting possible side effects (UK Patients and Public)
Ninlaro (ixazomib) and Revlimid (lenalidomide) are subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. If you get any side effects whilst taking the Ninlaro regimen, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed on this website or in the package leaflets. You can also report side effects directly via the Yellow Card Scheme at https://yellowcard.mhra.gov.uk. By reporting side effects you can help provide more information on the safety of these medicines.
Takeda Oncology,
and NINLARO are registered trademarks of Takeda Pharmaceutical Company Limited.
REVLIMID is a registered trademark of Celgene Corporation. Other trademarks are the property of their respective owners.
© Takeda UK Limited, 2021
Registered office: Takeda UK Limited, Building 3, Glory Park, Glory Park Avenue, Wooburn Green, Bucks, HP10 0DF
Registered in England and Wales No. 3362860
UK/IXA/1611/0088ao - Jan 2017
